Law Firm News

---

Law Firm News

Firm Name

News Title

News

News Date

25383 matches |  19993-19999 displayed

1  2856 2857 2858 2859 2860  3627

---

Young Conaway Stargatt & Taylor, LLP

YOUNG CONAWAY RANKS FIRST IN DELAWARE AMONG MIDLEVEL ASSOCIATES FOR SECOND YEAR IN A ROW
Young Conaway Stargatt & Taylor, LLP has ranked 1st in Delaware and 7th in the country when compared to other firms its size, according to the 2006 American Lawyer Midlevel Associates survey.

“The firm is pleased that Young Conaway has again been recognized by our associates as a great place to practice law,” said firm chairman James L. Patton, Jr.

The 2006 survey of third, fourth and fifth year associates at 175 firms across the United States probed into associates' levels of job satisfaction, including the interest and satisfaction levels of work; relations between associates and partners, training and guidance, openness about finances and strategies, billable hours policy; the firm's attitude toward pro bono work, and the likelihood of the associate being at the firm in two years.

Patton went on to say, “We are proud of the success the firm has achieved in developing a collegial and mentoring atmosphere among partners and associates. It is gratifying that our associates have praised Young Conaway for our emphasis on substantive work while also creating a balance that allows attorneys to pursue family, social and community interests outside the office.

08-16-2006

---

Wyrick Robbins Yates & Ponton LLP

Alec Donaldson speaks on Option Grant Practices
Wyrick Robbins partner Alexander M. Donaldson will be a speaker at the Research Triangle Chapter of the National Association of Corporate Directors on Tuesday, Sept. 12th at 8:00a.m. in Raleigh. His topic at the program will be "Option Grant Best Practices." Alec is a member of the firm's Capital Markets Practice Group.

08-16-2006

---

Grogan Graffam, P.C.

DALY ELECTED TO ACADEMY OF TRIAL LAWYERS
Grogan Graffam, P.C. announced that Leo Gerard Daly was recently elected to the Academy of Trial Lawyers of Allegheny County. Mr. Daly has been a shareholder since 1991 and a member of the firm’s Board of Directors since 2000.

The Academy of Trial Lawyers of Allegheny County was founded over 40 years ago as an organization of both plaintiffs’ and defense trial attorneys dedicated to the fair and efficient administration of justice. Membership is by invitation only and is limited to 250 attorneys.

Mr. Daly chairs the firm’s Litigation practice group. He is an experienced trial attorney concentrating in the commercial litigation, products liability, toxic tort litigation, environmental matters and insurance coverage issues. He received his B.A. from the University of Michigan in 1978 and his law degree from Case Western Reserve University in 1981. Mr. Daly is admitted to practice in Pennsylvania, West Virginia, Minnesota and South Dakota. He is a member of the Pennsylvania and American Bar Associations, and is the immediate past chair of the Allegheny County Bar Association’s Civil Litigation Section.

Mr. Daly and his family reside in Whitehall.

08-16-2006

---

Garan Lucow Miller P.C.

Garan Lucow Miller Law Firm Announces New Hire to Detroit Office
Garan Lucow Miller, P.C., with offices throughout Michigan, announces the hiring of attorney Todd D. Barry to the Detroit office. Mr. Barry joins the firm as an associate who practices workers’ compensation law.

Mr. Barry earned his B.A. degree from Michigan State University. He continued on to study at the University of Detroit Law School where he earned his J.D. in 1992. He previously practiced law with Levine, Benjamin in Southfield and Evans, Pletkovic & Rhodes, P.C. in Huntington Woods.

Mr. Barry is a member of the Michigan Trial Lawyers Association as well as the State Bar of Michigan.

Garan Lucow Miller, P.C. is a full-service law firm founded in 1948 with offices throughout Michigan. We provide legal services to businesses, individuals and municipalities. For a complete list, please visit our Web site at www.garanlucow.com.

08-16-2006

---

Davis & Munck, P.C.

Finnish monster band Lordi gets its own cola drink
Finland-After quenching Finland's thirst for success at the Eurovision Song Contest this year, monster hard rockers Lordi will be rewarded with its own cola soft drink, a local brewer said Wednesday.

Ritva Sinisalo, head of soft drinks products at brewer Olvi Group, said Lordi Cola - with labels featuring the monster-masked band members - is targeted to all consumers ""from babies to grandparents"" and is scheduled to hit shelves throughout the nation early next month.

Lordi took many Finns on an emotional roller-coaster earlier this year, with many locals fearing that sending the hideous monster band - complete with bloody gashes, protruding horns and war axes - to the Eurovision contest would tarnish Finland's image abroad.

But as the group's catchy tune ""Hard Rock Hallelujah"" ended Finland's 40-year winless streak at the Europe-wide music competition, the band became national heroes overnight.

""The Lordi phenomenon has brought the whole nation together,"" Sinisalo said. ""We just had a strong feeling that (Lordi Cola) could be 'the thing.'""

She added that singer Mr. Lordi - whose real name is Tomi Putaansuu - designed six different bottle labels for the drink, with five depicting individual band members and one showing the whole group. The drink will come in both regular and light versions.

With their latest album ""Arockalypse"" high on many European charts, Lordi will kick off a 45-day European tour in Stockholm on Sept. 16, according to the group's Web site.

08-16-2006

---

Davis & Munck, P.C.

Patent fight over blood-thinning drug Plavix could spell problems for Eli Lilly
The outcome of a federal court fight over a generic version of the popular blood-thinning drug Plavix could threaten one of Eli Lilly and Co.'s most promising pipeline medications.

Lilly's own blood-thinner, prasugrel, will face heightened competition if the cheaper, generic form of Plavix stays on the market. Lilly officials have said they expect to submit the medication to the Food and Drug Administration in late 2007.

Plavix's marketers Bristol-Myers Squibb Co. and Sanofi-Aventis SA are slated to square off against Apotex Inc. in a New York federal court Friday, in the hopes of forcing the Canadian generic company to halt sales of its version of the drug and recall product already sold.

Apotex's generic form of Plavix hit drug store shelves last week.

Prasugrel, which experts say could generate $1.2 billion (€0.94 billion) in sales in 2012, is part of a partnership between Lilly and Daiichi-Sankyo Co.

But it will be more difficult for prasugrel to reach that goal if Bristol-Myers and Sanofi-Aventis lose their injunction request, forcing Lilly's drug to compete against a cheap, generic version of Plavix.

Analysts said the research must show a significant difference between the two products to convince cost-cautious insurers that prasugrel merits a higher price tag.

""I think we're in an area where you have to be materially better to justify the cost,"" said George Farra, a principal with Woodley Farra Manion Portfolio Management in Indianapolis. ""If there isn't that much differentiation between the two, the cheaper version will be recommended by the insurance companies.""

To make sure the medication can sway hard-to-impress physicians and insurance companies, Lilly is enrolling 13,000 patients in a head-to-head study that pits Plavix against prasugrel.

If Lilly can prove its drug is better at preventing major cardiovascular problems among a high-risk population, that should help the pharmaceutical maker retain patients that might otherwise take the generic version of Plavix.

""The possibility that generic clopidogrel (Plavix) will become available earlier than expected underscores the validity of our clinical trial strategy,"" J. Anthony Ware, vice president and global brand development leader for prasugrel, told The Associated Press in a statement. ""We chose this strategy chiefly because we had anticipated that clopidogrel (generic Plavix) would be available on a generic basis for most of prasugrel's life cycle.""

Bear Stearns analyst John Boris called prasugrel Lilly's most important pipeline drug.

""If you're launching into a market, it's a lot better to launch into a market that's dominated by branded products,"" he said. ""It'd be much better for Lilly to compete head-to-head with Bristol, because the economics are based on a branded price.""

The generic form of Plavix costs around $124 (€97) for 30 tablets, compared with about $148 (€116) for the Bristol-Myers branded version.

Meanwhile, Bristol-Myers and Sanofi-Aventis are offering discounts on Plavix, hoping the drug will maintain its market share.

Sales of Plavix, the second-best selling drug in the world behind Pfizer Inc.'s cholesterol drug Lipitor, totaled $5.9 billion last year.

Plavix is made by Sanofi-Aventis but is sold in the U.S., Canada and other countries by Bristol-Myers. The medicine is Bristol-Myers' top-selling product.

A ruling on the injunction is expected to take several weeks

08-16-2006

---

Schiff Hardin LLP

SCHIFF HARDIN'S JOSHUA D. LEE NAMED TO TWO LEADERSHIP POSTS IN THE AMERICAN BAR ASSOCIATION TORT, TRIAL AND INSURANCE PRACTICE SECTION
Schiff Hardin associate Joshua D. Lee has been named Vice Chair of the American Bar Association's Tort Trial and Insurance Practice Section Toxic Tort & Environmental Law Committee. He simultaneously was named an Editorial Board Member of the Section's publication, TortSource.

08-16-2006

---

25383 matches |  19993-19999 displayed

1  2856 2857 2858 2859 2860  3627